MedKoo Biosciences

Medchem Research, Custom Synthesis,  Anticancer agents, Building Blocks, APIs, Intermediates

 

 

English | 中文   

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

 

 

 

Building blocks

Approved anticancer agents

Anticancer agents in trials

Anticancer molecular libraries

Drug APIs

Drug intermediates

Bio-reagents

New products from China

 

 

 

 

 

MedKoo's special collection

Anticancer molecular libraries

The following anticancer molecular libraries are collected by MedKoo's scientists. All information is directly from public available sources. We can not guarantee  for the accuracy for the information we list here. Note: Some molecules listed in our website may be protected under valid patents. Those molecules may be only used for research proposes or used as reference standards, should not be used for commercial proposes. It's entirely user's responsibility to properly use the agents.

For availability and quotation, please contact: sales@medkoo.com

 Library name

 Brief description

Arsenic anticancer agents

Arsenic, a known human carcinogen, can induce tumors of the skin, urinary bladder, liver and lung etc.. On the other hand, arsenic is also a novel promising anticancer agent, and can be used effectively to treat acute promyelocytic leukemia (APL) and some other tumors.

 

Aurora kinase inhibitors

 

Aurora kinases are overexpressed in a variety of tumor cell lines, suggesting their potential role as cancer target for molecular therapies.

 

Aziridine analogues

 

Compound with aziridine substructure unit have potential anticancer activity.

BCL-2  inhibitors

(B-cell lymphoma 2)

BCL-2 family of proteins plays critical roles in human cancers,, suggesting that the discovery of specific agents targeting Bcl-2 family proteins would be extremely valuable for cancer therapy. 

 

BCR-ABL inhibitors

(Bcr-Abl tyrosine kinase inhibitors)

The BCR-ABL chimeric protein is thought to play a central role in the pathogenesis of Philadelphia (Ph) chromosome-positive leukemias, notably chronic myeloid leukemia (CML). BCR-ABL tyrosine kinase  may be suitable targets for  cancer therapy.

 

CA  inhibitors

(carbonic anhydrase)

Carbonic anhydrase inhibitors can selectively block the enzyme activity of cancer-related isoforms, namely CA IX and CA XII. Thus, CA inhibitors may have potential anticancer activity

 

Cell cycle checkpoint inhibitors

 

Cell cycle checkpoints are activated in response to DNA damage. Their role consists in blocking the cell cycle to allow time for DNA repair. Among the regulators of the G2 checkpoint, Checkpoint 1 kinase (Chk1) plays a major role. Chk1 inhibitors as potential useful compounds can enhance the antitumor efficiency of DNA damaging agents.

 

c-Met inhibitor

(mesenchymal-epithelial transition factor)

c-Met is a receptor tyrosine kinase that plays a key role in several cellular processes but has also been found to be overexpressed and mutated in different human cancers.  The c-MET inhibitor may have a significant therapeutic potential.

 

 Dual  kinase inhibitors

Dual receptor tyrosine kinase inhibitors includes:

VEGF/EGFR inhibitors; EGFR/ErbB-2 inhibitors; EGFR and HER2  inhibitors; ErbB1 (EGFR/HER1)  inhibitors, ErbB2 (HER2/neu) inhibitors,

 

 Farnesyl  transferase inhibitors

Farnesyl transferase inhibitors are a new class of biologically active anticancer drugs. The inhibition of farnesylation of a wide range of target proteins will ultimately result in cell growth arrest. 

 

 FLT3 inhibitors

(FMS-like tyrosine kinase 3)

FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase (TK) expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system.

FLT3 inhibitors have some potential anticancer activity.

 

HDAC  inhibitors

(Histone deacetylase)

 

Histone deacetylases (HDACs) catalyze the removal of acetyl groups from histones and contribute to transcriptional repression.   HDAC inhibitors can induce cell-cycle arrest, promote differentiation, and stimulate tumor cell death.

 

Hypoxia cytotoxic agents

Hypoxia is associated with tumour hypoxia including: resistance to ionising radiation, resistance to chemotherapy and the magnification of mutated p53. As such this provides a significant target for drug discovery particularly for tumour-targeting agents.

 

IGF-IR inhibitors

(insulin-like growth factor receptor)

 

IGF-IR and insulin receptor contribute to tumorigenicity, proliferation, metastasis, and drug resistance. As IGF signaling has been recognized to play an important role in human cancer, the IGF-IR  is currently the focus of intensive research aimed at developing novel antitumor agents.

 

IMPDH  inhibitors

(Inosine Monophosphate Dehydrogenase )

IMPDH is the rate-limiting enzyme for de novo purine synthesis. Inhibition of IMPDH results in reduced levels of guanylates, resulting in the inhibition tumor cell growth in vitro and in vivo.

 

 JNK  inhibitors

(c-Jun-N-Terminal Kinase)

 

Inhibitors of c-Jun-N-Terminal Kinase (JNK) have many potential therapeutic indications ranging from neurodegenerative disease, to metabolic disorders, inflammation, cardiovascular disease, and cancer.  

 

KSP inhibitors

(Kinesin  spindle protein)

 

Kinesin spindle protein (KSP) plays a critical role in mitosis as it mediates centrosome separation and bipolar spindle assembly and maintenance. Inhibition of KSP function leads to cell cycle arrest at mitosis with the formation of monoastral microtubule arrays, and ultimately, to cell death.

 

 LTB4 receptor antagonists

(leukotriene B4  receptor)

 

The blockade of the LTB(4)-signaling pathway induces apoptosis via the inhibition of ERK activation in colon cancer cells. The LTB(4)-signaling pathway might be a new therapeutic target for colon cancer.

 

MGMT/AGT inhibitors

(O6-methylguanine DNA methyltransferase/O6-alkylguanine DNA alkyltransferase )

 

MGMT/AGT removes alkyl adducts from the O6-position of guanine in DNA. Expression of MGMT in human cancers has been associated with resistance to therapies using alkylating agents. MGMT/AGT inhibitors may enhance efficacy of alkylatin anticancer agents

 

 

 MMP  inhibitors

(atrix metalloproteinases)

 

The matrix metalloproteinases (MMPs) are involved in many aspects of both physiological cellular processes and pathological situations, such as tumor growth, invasion and metastasis. MMPs have been considered prognostic factors in various types of cancer as well as promising targets for cancer therapy.

 

NK1 receptor antagonists

(neurokinin-1 receptor antagonist) 

The presence of functional NK1 receptors has been documented in malignant brain tumours of glial origin.  It has been suggested that SP receptor antagonists application might be useful in attempts directed at anti-cancer therapy.

 

Nitrogen mustard

The nitrogen mustards are bifunctional alkylating agents which, although used extensively in cancer chemotherapy, are themselves highly carcinogenic

 

PARP inhibitors

(Poly (ADP-ribose) polymerase (PARP))

 PARP inhibition is associated with increased sensitivity to DNA-alkylating agents, topoisomerase I poisons and ionising radiation.

 

Phosphamide  mustard

 

Phosphamide  mustard belongs to alkylation agents.

 

 PLK-1  inhibitors

(polo-like kinase 1 )

PLK1 is overexpressed in human tumours and has prognostic potential in cancer, indicating its involvement in carcinogenesis and its potential as a therapeutic target.

 

Quinazoline Kinase inhibitors

 

4-anilinoquinazoline and its analogues  are potent and selective kinase inhibitors with potential anticancer activity.

 

SPR  modulators

(Selective progesterone receptor)

Selective progesterone receptor modulators (SPRMs) represent a new class of progesterone receptor ligands.  SPRMs have the potential to become a novel treatment of uterine fibroids, endometriosis and cancer.

 

 STAT 3 inhibitors

(Signal transducer and activator of transcription 3)

STAT-3  is constitutively activated by aberrant upstream tyrosine kinase activities in a broad spectrum of human tumors, and it has been identified as a promising target for cancer drug discovery.

 

STS inhibitors

(Steroid sulfatase)

STS  inhibitors are potential anticancer agents.

Survivin inhibitors

Survivin belongs to the inhibitor of apoptosis protein (IAP) family that acts as a suppressor of apoptosis and plays a central role in cell division. Survivin is currently undergoing extensive investigation as a novel therapeutic target

 

TS inhibitors

(Thymidylate synthase)

Thymidylate synthase (TS) is a well-validated target for cancer chemotherapy.

 

Vascular disrupting agents (VDAs)

Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and shutdown blood supply to solid tumors, causing extensive tumor cell necrosis.

 

 

Contact MedKoo:

Email: sales@medkoo.com

 

Arsenic anticancer agents

Aurora kinase inhibitors

Aziridine analogues

BCL-2  inhibitors

BCR-ABL inhibitors

CA  inhibitors

Checkpoint inhibitors

c-Met inhibitor

Dual kinase inhibitors

Farnesyl  transferase inhibitors

FLT3 inhibitors

HDAC  inhibitors

Hypoxia cytotoxic agents

IGF-IR inhibitors

IMPDH  inhibitors

JNK  inhibitors

KSP inhibitors

LTB4 receptor antagonists

MGMT/AGT inhibitors

MMP  inhibitors

Nitrogen mustard

NK1 receptor antagonists

PARP inhibitors

Phosphamide  mustard

PLK-1  inhibitors

Quinazoline Kinase inhibitors

SPR  modulators

STAT 3 inhibitors

STS inhibitors

Survivin inhibitors

TS inhibitors

Vascular disrupting agents

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

© MedKoo Biosciences. All Rights Reserved

free hit counter